Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Dr. Reddy’s expansion plans for API production
Unrelated to the inspection of
the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe
Cabazitaxel –The Market Overcrowding Begins
Many companies have been actively developing Cabazitaxel (Jevtana Kit®), a prostate cancer drug
